ImmunoVaccine Technologies Receives European Patent Allowance
All of the claims filed for the patent were allowed following modification of claims 43, 44 and 45. These claims were modified to conform to European patent presentation.
Upon receiving the notification Dr. Warwick Kimmins, President and CEO stated, "The issuance of the European patent complements the US patent protection for our VacciMax(R) vaccine platform technology and is good news for IVT's shareholders and our industry partners."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.